Do analysts rate MOR or PHAT?

Phathom Pharmaceuticals has a consensus price target of $22.86, suggesting a potential upside of 142.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Phathom Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Do analysts recommend RGC or PHAT?

Phathom Pharmaceuticals has a consensus price target of $22.86, indicating a potential upside of 142.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phathom Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has better earnings & valuation, RGC or PHAT?

Regencell Bioscience has higher earnings, but lower revenue than Phathom Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Phathom Pharmaceuticals $239.66M 3.18 -$221.25M -$1.28 N/A

Is RGC or PHAT more profitable?

Regencell Bioscience has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Phathom Pharmaceuticals -41.34% N/A -20.81%

Phathom Pharmaceuticals (PHAT) Competitors

$9.43 -0.07 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$9.43 0.00 (-0.05%)

As of 07:30 PM Eastern

Compare

PHAT vs. MOR, RGC, ATAI, SUPN, and PBH

Should you buy Phathom Pharmaceuticals stock or one of its competitors? Phathom Pharmaceuticals's main competitors and comparable companies include MorphoSys (MOR), Regencell Bioscience (RGC), Atai Beckley (ATAI), Supernus Pharmaceuticals (SUPN), and Prestige Consumer Healthcare (PBH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phathom Pharmaceuticals compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Phathom Pharmaceuticals has a consensus price target of $22.86, suggesting a potential upside of 142.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Phathom Pharmaceuticals' average media sentiment score of 0.86 beat MorphoSys' score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Phathom Pharmaceuticals	Positive

MorphoSys has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Phathom Pharmaceuticals	$239.66M	3.18	-$221.25M	-$1.28	N/A

Phathom Pharmaceuticals has a net margin of -41.34% compared to MorphoSys' net margin of -226.79%. Phathom Pharmaceuticals' return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats MorphoSys on 12 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Regencell Bioscience has higher earnings, but lower revenue than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Phathom Pharmaceuticals	$239.66M	3.18	-$221.25M	-$1.28	N/A

Regencell Bioscience has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Phathom Pharmaceuticals has a consensus price target of $22.86, indicating a potential upside of 142.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Regencell Bioscience has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

In the previous week, Regencell Bioscience had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 1 mentions for Regencell Bioscience and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.86 beat Regencell Bioscience's score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Phathom Pharmaceuticals	Positive

Summary

Phathom Pharmaceuticals beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Atai Beckley presently has a consensus target price of $10.56, suggesting a potential upside of 45.00%. Phathom Pharmaceuticals has a consensus target price of $22.86, suggesting a potential upside of 142.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Phathom Pharmaceuticals has higher revenue and earnings than Atai Beckley. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	660.11	-$660.05M	-$2.18	N/A
Phathom Pharmaceuticals	$239.66M	3.18	-$221.25M	-$1.28	N/A

Atai Beckley has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Atai Beckley had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 1 mentions for Atai Beckley and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.86 beat Atai Beckley's score of 0.82 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Positive
Phathom Pharmaceuticals	Positive

Phathom Pharmaceuticals has a net margin of -41.34% compared to Atai Beckley's net margin of -14,938.36%. Phathom Pharmaceuticals' return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Summary

Phathom Pharmaceuticals beats Atai Beckley on 11 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Supernus Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Phathom Pharmaceuticals' net margin of -41.34%. Supernus Pharmaceuticals' return on equity of 11.13% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Phathom Pharmaceuticals currently has a consensus target price of $22.86, suggesting a potential upside of 142.39%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 48.09%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Phathom Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Supernus Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$239.66M	3.18	-$221.25M	-$1.28	N/A
Supernus Pharmaceuticals	$718.95M	3.43	-$38.55M	-$1.92	N/A

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 5 mentions for Supernus Pharmaceuticals and 0 mentions for Phathom Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.92 beat Phathom Pharmaceuticals' score of 0.86 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Positive
Supernus Pharmaceuticals	Positive

Summary

Supernus Pharmaceuticals beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Prestige Consumer Healthcare had 6 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for Prestige Consumer Healthcare and 0 mentions for Phathom Pharmaceuticals. Prestige Consumer Healthcare's average media sentiment score of 1.30 beat Phathom Pharmaceuticals' score of 0.86 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Prestige Consumer Healthcare	Positive
Phathom Pharmaceuticals	Positive

Prestige Consumer Healthcare has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.17	$190.30M	$3.57	13.95
Phathom Pharmaceuticals	$239.66M	3.18	-$221.25M	-$1.28	N/A

Prestige Consumer Healthcare presently has a consensus price target of $70.75, indicating a potential upside of 42.09%. Phathom Pharmaceuticals has a consensus price target of $22.86, indicating a potential upside of 142.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Prestige Consumer Healthcare has a net margin of 15.57% compared to Phathom Pharmaceuticals' net margin of -41.34%. Prestige Consumer Healthcare's return on equity of 11.39% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Prestige Consumer Healthcare has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

Prestige Consumer Healthcare beats Phathom Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$768.56M	$12.20B	$7.24B	$12.89B
Dividend Yield	N/A	2.59%	2.54%	9.14%
P/E Ratio	-7.37	782.23	270.04	25.38
Price / Sales	3.18	758.70	598.85	78.71
Price / Cash	N/A	90.26	77.07	52.39
Price / Book	-1.54	11.00	10.92	6.40
Net Income	-$221.25M	$2.81B	$3.48B	$358.18M
7 Day Performance	0.43%	-0.12%	-0.02%	0.69%
1 Month Performance	10.29%	4.34%	3.02%	-0.78%
1 Year Performance	-24.14%	7.58%	22.73%	13.38%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	3.3665 of 5 stars	$9.43 -0.7%	$22.86 +142.4%	-23.0%	$768.56M	$239.66M	N/A	110
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RGC Regencell Bioscience	0.0674 of 5 stars	$5.51 +0.2%	N/A	-48.0%	$2.72B	N/A	N/A	10
ATAI Atai Beckley	3.3189 of 5 stars	$7.34 +0.7%	$10.56 +43.8%	+61.7%	$2.70B	$4.09M	N/A	80	News Coverage Options Volume
SUPN Supernus Pharmaceuticals	4.392 of 5 stars	$44.21 +1.1%	$62.83 +42.1%	-5.4%	$2.54B	$830.44M	N/A	580

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 9/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. MOR, RGC, ATAI, SUPN, and PBH

How does Phathom Pharmaceuticals compare to MorphoSys?

Summary

How does Phathom Pharmaceuticals compare to Regencell Bioscience?

Summary

How does Phathom Pharmaceuticals compare to Atai Beckley?

Summary

How does Phathom Pharmaceuticals compare to Supernus Pharmaceuticals?

Summary

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. MOR, RGC, ATAI, SUPN, and PBH

How does Phathom Pharmaceuticals compare to MorphoSys?

Do analysts rate MOR or PHAT?

Does the media favor MOR or PHAT?

Which has preferable earnings & valuation, MOR or PHAT?

Is MOR or PHAT more profitable?

Which has more volatility and risk, MOR or PHAT?

Do institutionals & insiders hold more shares of MOR or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Regencell Bioscience?

Which has better earnings & valuation, RGC or PHAT?

Is RGC or PHAT more profitable?

Do institutionals and insiders believe in RGC or PHAT?

Do analysts recommend RGC or PHAT?

Which has more volatility & risk, RGC or PHAT?

Does the media refer more to RGC or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Atai Beckley?

Do analysts prefer ATAI or PHAT?

Do insiders & institutionals have more ownership in ATAI or PHAT?

Which has higher valuation & earnings, ATAI or PHAT?

Which has more volatility & risk, ATAI or PHAT?

Does the media favor ATAI or PHAT?

Is ATAI or PHAT more profitable?

Summary

How does Phathom Pharmaceuticals compare to Supernus Pharmaceuticals?

Is PHAT or SUPN more profitable?

Do institutionals & insiders hold more shares of PHAT or SUPN?

Do analysts recommend PHAT or SUPN?

Which has more risk and volatility, PHAT or SUPN?

Which has better earnings and valuation, PHAT or SUPN?

Does the media refer more to PHAT or SUPN?

Summary

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Do insiders and institutionals have more ownership in PBH or PHAT?

Does the media refer more to PBH or PHAT?

Which has stronger earnings and valuation, PBH or PHAT?

Do analysts rate PBH or PHAT?

Is PBH or PHAT more profitable?

Which has more volatility and risk, PBH or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools